Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
» ONXX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ONXX Guru Trades in Q1 2013

Pioneer Investments 22,100 sh (New)
Jim Simons 30,333 sh (New)
RS Investment Management 19,800 sh (+330.43%)
Mariko Gordon 4,000 sh (unchged)
Vanguard Health Care Fund 1,022,700 sh (unchged)
Mariko Gordon 4,149 sh (unchged)
Louis Moore Bacon Sold Out
Steven Cohen 107,678 sh (-0.85%)
Columbia Wanger 1,127,000 sh (-0.88%)
» More
Q2 2013

ONXX Guru Trades in Q2 2013

Steven Cohen 496,428 sh (+361.03%)
Pioneer Investments 79,300 sh (+258.82%)
Mariko Gordon 7,138 sh (+72.04%)
Vanguard Health Care Fund 1,022,700 sh (unchged)
Columbia Wanger 1,127,000 sh (unchged)
Mariko Gordon 7,500 sh (unchged)
Stanley Druckenmiller Sold Out
Jim Simons Sold Out
RS Investment Management 18,400 sh (-7.07%)
» More
Q3 2013

ONXX Guru Trades in Q3 2013

Mario Gabelli 644,979 sh (New)
Prem Watsa 4,500 sh (New)
Louis Moore Bacon 100,000 sh (unchged)
Vanguard Health Care Fund 1,022,700 sh (unchged)
Columbia Wanger Sold Out
Pioneer Investments Sold Out
RS Investment Management Sold Out
Steven Cohen Sold Out
Mariko Gordon Sold Out
» More
Q4 2013

ONXX Guru Trades in Q4 2013

Mario Gabelli Sold Out
Vanguard Health Care Fund Sold Out
Prem Watsa Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ONXX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2013-09-30 New Buy0.47%$110.99 - $136.03 $ 124.7-2%644979
Prem Watsa 2013-09-30 New Buy0.04%$110.99 - $136.03 $ 124.7-2%4500
Mariko Gordon 2013-09-30 Sold Out 0.03%$110.99 - $136.03 $ 124.7-2%0
Mariko Gordon 2013-06-30 Add 72.04%0.01%$81.76 - $100.37 $ 124.736%7138
Vanguard Health Care Fund 2012-09-30 Reduce -24.4%0.1%$64.73 - $85.82 $ 124.769%1022700
George Soros 2011-06-30 Sold Out $33.565 - $45.37 $ 124.7230%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Onyx Pharmaceuticals, Inc.

Mario Gabelli Comments on Onyx Pharmaceuticals Inc. - Jan 03, 2014

Onyx Pharmaceuticals Inc. (4.2%) (ONXX - $124.67 - NASDAQ) (ONXX) is a San Francisco based biotechnology company engaged in the development of cancer related drugs. On August 25, 2013, Amgen Inc. announced a $125.00 cash tender offer for the shares of Onyx. The offer came at the end of negotiations, which began in early June and were confirmed by the company on June 30. The tender, which commenced on September 3, is expected to close on October 1 of this year.



 



From Mario Gabelli's third quarter 2013 commentary.



Check out Mario Gabelli latest stock trades

Top Ranked Articles about Onyx Pharmaceuticals, Inc.

Mario Gabelli Comments on Onyx Pharmaceuticals Inc.
Onyx Pharmaceuticals Inc. (4.2%) (ONXX - $124.67 - NASDAQ) (ONXX) is a San Francisco based biotechnology company engaged in the development of cancer related drugs. On August 25, 2013, Amgen Inc. announced a $125.00 cash tender offer for the shares of Onyx. The offer came at the end of negotiations, which began in early June and were confirmed by the company on June 30. The tender, which commenced on September 3, is expected to close on October 1 of this year. Read more...
Columbia Wanger’s Third Quarter Selling
Columbia Wanger Asset Management is averaging a 12-month return of 19.09%, according to the GuruFocus Scoreboard. The updated portfolio lists 296 stocks, 16 of them new, a total value of $24.82 billion, and a quarter-over-quarter turnover of 6%. The portfolio is weighted with the top three sectors: industrials at 25.7%, technology at 19.1% and consumer cyclical at 13.4%. Here are the details on four high-impact sells made by Columbia Wanger in the third quarter of 2013, starting with Lululemon Athletica Inc., the yoga and athletic apparel company that has had a string of quality issues. The company reported financial results for the second quarter fiscal 2013, ended Aug. 4, 2013, with net revenue at $344.5 million, up 22% from last year’s same quarter at $282.6 million. The company’s gross profit was $186 million, an increase of 19%. Earnings of $0.39 per diluted per share for the quarter were based on a quarterly net income of $56.5 million, down from $57.2 million in the same quarter Read more...

Ratios

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:OX1.Germany
Onyx Pharmaceuticals, Inc was incorporated in California in February 1992 and reincorporated in Delaware in May 1996. The Company is a biopharmaceutical company developing therapies that target the molecular mechanisms that cause cancer. Through the Company's internal research programs and in conjunction with its collaborators, the Company is applying its expertise to develop and commercialize innovative therapies that target the molecular mechanisms that cause cancer. The Company's commercially available products are Nexavar (sorafenib) tablets, Stivarga (regorafenib) tablets and Kyprolis (carfilzomib) for Injection. Nexavar (sorafenib) tablets, is approved in multiple countries for unresectable liver cancer and advanced kidney cancer. Stivarga (regorafenib) tablets, a Bayer compound, is approved in the United States for the treatment of metastatic colorectal cancer (mCRC) and for the treatment of advanced gastrointestinal stromal tumors (GIST); and is under regulatory review for mCRC in the European Union and Japan and for the treatment of GIST in Japan. Kyprolis (carfilzomib) for Injection, is approved in the United States for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent (IMiD), and have demonstrated disease progression on or within 60 days of completion of the last therapy. . The Company is subject to federal, state and local laws and regulations governing the use, generation, manufacture, storage, air emission, effluent discharge, handling and disposal of certain hazardous or potentially hazardous materials.
» More Articles for ONXX

Headlines

Articles On GuruFocus.com
Mario Gabelli Comments on Onyx Pharmaceuticals Inc. Jan 03 2014 
Columbia Wanger’s Third Quarter Selling Nov 20 2013 
6 New Stock Picks from Prem Watsa Nov 19 2013 
Edward Owens’ Vanguard Health Care Fund Does More Shedding than Adding in Third Quarter Nov 01 2012 
ONYX Pharmaceuticals Inc. (ONXX) EVP & COO Laura Brege sells 12,500 Shares Jan 20 2011 
ONYX Pharmaceuticals Inc. (ONXX) CFO Matthew K Fust sells 1,812 Shares Jan 07 2011 
ONYX Pharmaceuticals Inc. (ONXX) President & CEO N Anthony Coles sells 13,669 Shares Dec 08 2010 
ONYX Pharmaceuticals Inc. (ONXX) EVP & COO Laura Brege sells 25,000 Shares Nov 10 2010 
ONYX Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 03 2010 
ONYX Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 04 2010 

More From Other Websites
Bayer and Onyx Report Phase 3 Study Results of NEXAVAR® (sorafenib) as Adjuvant Treatment for... Mar 11 2014
Amgen 4Q profit leaps 30 percent on higher sales Jan 28 2014
Amgen 4Q profit leaps 30 percent on higher sales Jan 28 2014
Amgen Q4 profit leaps 30 percent on higher sales Jan 28 2014
Amgen Q4 profit leaps 30 percent on higher sales Jan 28 2014
Best Call of 2013: Onyx Pharmaceuticals Dec 31 2013
The International Myeloma Foundation Announces Partnership with Onyx Pharmaceuticals to Support... Dec 06 2013
BioMarin: Where Biotech and Rodney Dangerfield Cross Paths Nov 26 2013
3 Monday Morning Biotech Movers Nov 25 2013
2 Biotech Stocks With Strong Buyout Potential Nov 25 2013
U.S. FDA Approves NEXAVAR® (sorafenib) for the Treatment of Patients with Locally Recurrent or... Nov 22 2013
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of... Nov 07 2013
Karyopharm Therapeutics IPO Looks Promising Nov 06 2013
Biotech Stock Bubble Talk Deflated By Cost-Conscious Buyers Oct 02 2013
ONYX PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Triggering... Oct 01 2013
Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer Oct 01 2013
Trade-Ideas: Onyx Pharmaceuticals (ONXX) Is Today's "Water-Logged And Getting Wetter" Stock Sep 30 2013
Amgen's 10 Billion Dollar Molecule Sep 30 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide